GSK plc GSK announced that the FDA expanded Boostrix’s label for immunization during pregnancy to help prevent pertussis (whooping cough) in infants not older than two months. Following the label ...
(RTTNews) - The FDA has approved GSK plc's (GSK) Boostrix vaccine for immunization during the third trimester of pregnancy to prevent pertussis, commonly known as whooping cough, in infants younger ...
The FDA has approved use of GlaxoSmithKline’s Boostrix (Tdap) vaccine for use during the third trimester of pregnancy, for prevention of pertussis (whooping cough) in infants younger than two months ...
PHILADELPHIA, PA--(MARKET WIRE)--Dec 8, 2008 -- GlaxoSmithKline (NYSE:GSK - News) announced today that the U.S. Food and Drug Administration (FDA) has approved BOOSTRIX® [Tetanus Toxoid, Reduced ...
NEW YORK, July 8, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved BOOSTRIX® [Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine, Adsorbed (Tdap)] ...
BOOSTRIX (Tetanus and reduced diphtheria toxoid, acellular pertussis vaccine) by GlaxoSmithKline GlaxoSmithKline's combination vaccine Boostrix (tetanus toxoid, reduced diphtheria toxoid, and ...
Researchers have studied thousands of pregnant women who got the Tdap vaccine, which aims to prevent tetanus, diphtheria and pertussis, aka whooping cough. The vaccine is recommended for pregnant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback